NCT06589830View on ClinicalTrials.gov

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

80

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions

Colorectal Cancer MetastaticAdvanced Colorectal Cancer

Interventions

DRUG

TL938 Capsules

Oral administration

DRUG

Trastuzumab

Intravenous (IV) infusion

All Listed Sponsors

lead

Suzhou Teligene Ltd.

INDUSTRY